TY - JOUR T1 - Using COVID-19 deaths as a surrogate to measure the progression of the pandemics JF - medRxiv DO - 10.1101/2020.09.27.20202564 SP - 2020.09.27.20202564 AU - Carlos Hernandez-Suarez AU - Efren Murillo-Zamora Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/30/2020.09.27.20202564.abstract N2 - The IFR (Infection Fatality Risk) is one of the most important parameters of an infectious disease. If properly estimated, the observed number of deaths divided by the IFR can be used to estimate the current number of infections and, if immunity is permanent, we can estimate the fraction of susceptible which can be used to plan reopening of activities and vaccine deployment, when these become available. Here we suggest how to use the observed deaths by COVID-19 in an arbitrary population as a surrogate for the progression of the epidemic with the purpose of decision making. We compare several estimates of IFR for SARS-CoV-2 with our estimate that uses the number of additional deaths in households in a database population of 159,150 laboratory-confirmed (RT-qPCR) COVID-19 by SARS-COV-2 in Mexico. The main result is that if the number of deaths in a region is close to 2 per thousand individuals, the fraction of remaining susceptible may be too small for the vaccine to make a difference in the total number of infected.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is part of the DFID-UNHCR-World Bank program "Building the Evidence on Protracted Forced Displacement: A Multi-Stakeholder Partnership". The program is funded by UK aid from the United Kingdom's Department for International Development (DFID), it is managed by the World Bank Group (WBG) and was established in partnership with the United Nations High Commissioner for Refugees (UNHCR). The scope of the program is to expand the global knowledge on forced displacement by funding quality research and disseminating results for the use of practitioners and policy makers. This work does not necessarily reflect the views of DFID, the WBG or UNHCR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo open data available ER -